for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Reviva Pharmaceuticals Holdings, Inc.

RVPH.OQ

Latest Trade

3.85USD

Change

0.17(+4.62%)

Volume

7,731

Today's Range

3.75

 - 

3.88

52 Week Range

3.29

 - 

11.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.68
Open
3.75
Volume
7,731
3M AVG Volume
1.39
Today's High
3.88
Today's Low
3.75
52 Week High
11.47
52 Week Low
3.29
Shares Out (MIL)
13.98
Market Cap (MIL)
51.45
Forward P/E
-5.58
Dividend (Yield %)
--

Next Event

Q4 2021 Reviva Pharmaceuticals Holdings, Inc. Earnings Release

Latest Developments

More

Reviva Pharmaceuticals Holdings Reports Third Quarter 2021 Financial Results

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results

Reviva Announces Full Details Of Positive Phase 2 Clinical Trial Results For Acute Schizophrenia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. It uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The Company's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.

Industry

Business Services

Contact Info

19925 Stevens Creek Blvd., Suite 100

CUPERTINO, CA

95014

United States

+1.408.5018881

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-0.840
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-10.61
Return on Equity (TTM)
-10.41

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up